Trial Profile
A Randomized, Placebo-Controlled Trial of HPV Vaccination to Reduce Cervical High-Grade Squamous Intraepithelial Lesions Among HIV-Infected Women Participating in an HPV Test-and-Treat Program (COVENANT)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs V 503 (Primary)
- Indications Cervical intraepithelial neoplasia; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms COVENANT
- 22 Jan 2024 Planned primary completion date changed from 2 Dec 2025 to 2 Dec 2024.
- 20 Dec 2023 Planned primary completion date changed from 15 Mar 2025 to 2 Dec 2025.
- 20 Dec 2023 Status changed from recruiting to active, no longer recruiting.